GT201400094A - Formulación de liberación inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)-fenil]-benzamida - Google Patents

Formulación de liberación inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)-fenil]-benzamida

Info

Publication number
GT201400094A
GT201400094A GT201400094A GT201400094A GT201400094A GT 201400094 A GT201400094 A GT 201400094A GT 201400094 A GT201400094 A GT 201400094A GT 201400094 A GT201400094 A GT 201400094A GT 201400094 A GT201400094 A GT 201400094A
Authority
GT
Guatemala
Prior art keywords
methyl
piridinil
imidazol
amino
benzamida
Prior art date
Application number
GT201400094A
Other languages
English (en)
Inventor
Upkar Bhardwaj
Mangesh Sadashiv Bordawekar
Ann Reese Comfort
Ping Li
Shoufeng Li
Alexey Makarov
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of GT201400094A publication Critical patent/GT201400094A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE DA A CONOCER UNA FORMA DE DOSIFICACIÓN SÓLIDA DEL NILOTINIB QUE COMPRENDE: (I) UN NÚCLEO QUE COMPRENDE LA 4-METIL-3-[[4-(3-PIRIDINIL)-2-PIRIMIDINIL]-AMINO]-N-[5-(4-METIL-1H-IMIDAZOL-1-IL)-3-(TRIFLUORO-METIL)-FENIL]-BENZAMIDA, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LA MISMA, Y EXCIPIENTES; Y (II) CUANDO MENOS UN POLÍMERO, RECUBRIENDO ESTE POLÍMERO AL NÚCLEO, EN DONDE SE DEMORA LA DESINTEGRACIÓN DE LA FORMA DE DOSIFICACIÓN SÓLIDA MENCIONADA.
GT201400094A 2011-11-14 2014-05-14 Formulación de liberación inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)-fenil]-benzamida GT201400094A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161559281P 2011-11-14 2011-11-14

Publications (1)

Publication Number Publication Date
GT201400094A true GT201400094A (es) 2017-09-28

Family

ID=47324402

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400094A GT201400094A (es) 2011-11-14 2014-05-14 Formulación de liberación inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)-fenil]-benzamida

Country Status (22)

Country Link
EP (1) EP2779995A1 (es)
JP (1) JP6275645B2 (es)
KR (1) KR20140093230A (es)
CN (1) CN103930094A (es)
AR (1) AR088844A1 (es)
BR (1) BR112014011518A2 (es)
CA (1) CA2855503A1 (es)
CL (1) CL2014001247A1 (es)
CO (1) CO6960546A2 (es)
EA (1) EA201490960A1 (es)
GT (1) GT201400094A (es)
HK (1) HK1197025A1 (es)
IL (1) IL232480A0 (es)
IN (1) IN2014DN03416A (es)
MA (1) MA35636B1 (es)
MX (1) MX2014005874A (es)
PE (1) PE20141337A1 (es)
SG (2) SG10201707768RA (es)
TN (1) TN2014000177A1 (es)
TW (1) TWI574690B (es)
WO (1) WO2013074432A1 (es)
ZA (1) ZA201402756B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
JP7378279B2 (ja) * 2019-11-18 2023-11-13 日本化薬株式会社 ニロチニブを有効成分とする医薬錠剤及びその製造方法
JP7489849B2 (ja) 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
WO2012164578A1 (en) * 2011-06-02 2012-12-06 Hetero Research Foundation Compositions and methods for preparing immediate release formulations of nilotinib

Also Published As

Publication number Publication date
CO6960546A2 (es) 2014-05-30
KR20140093230A (ko) 2014-07-25
CL2014001247A1 (es) 2014-10-17
ZA201402756B (en) 2015-04-29
EA201490960A1 (ru) 2014-08-29
NZ623844A (en) 2016-09-30
TWI574690B (zh) 2017-03-21
CA2855503A1 (en) 2013-05-23
MX2014005874A (es) 2014-06-23
TN2014000177A1 (en) 2015-09-30
CN103930094A (zh) 2014-07-16
SG11201401476TA (en) 2014-10-30
SG10201707768RA (en) 2017-10-30
AR088844A1 (es) 2014-07-10
BR112014011518A2 (pt) 2017-05-16
TW201325594A (zh) 2013-07-01
AU2012339829A1 (en) 2014-05-29
IL232480A0 (en) 2014-06-30
JP2014533283A (ja) 2014-12-11
IN2014DN03416A (es) 2015-06-26
HK1197025A1 (en) 2015-01-02
MA35636B1 (fr) 2014-11-01
JP6275645B2 (ja) 2018-02-07
PE20141337A1 (es) 2014-10-16
AU2012339829B2 (en) 2016-05-12
EP2779995A1 (en) 2014-09-24
WO2013074432A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
GT201300309A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
NI201600098A (es) Composiciones farmacéuticas que comprenden azd9291
PE20141822A1 (es) Inhibidor de la quinasa reguladora de la senal de apoptosis
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
NZ600310A (en) 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
EA201291421A1 (ru) Пероральные фармацевтические лекарственные формы, содержащие дабигатрана этексилат и его фармацевтически приемлемые соли
PE20140389A1 (es) Composiciones y metodos para el tratamiento de la mielofibrosis
UA111599C2 (uk) Композиція каспофунгіну
GT201400094A (es) Formulación de liberación inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)-fenil]-benzamida
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
EA201590142A1 (ru) Фармацевтические лекарственные формы, содержащие 5-хлор-n-({(5s)-2-оксо-3-[4-(3-оксо-4-морфолинил)фенил]-1,3-оксазолидин-5-ил}метил)-2-тиофен-карбоксамид
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
PH12017501832A1 (en) Stabilized pharmaceutical composition
CO2018002046A2 (es) Nueva composición oral de libreación retardada dual de dexlansoprazol
PH12016500716B1 (en) Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
UA97982U (uk) Лікарський засіб седативної дії у вигляді таблеток
TH152470A (th) สูตรตำรับ 4-เมธิล-3-[[4-(3-ไพริดินิล-2-ไพริมิดินิลอะมิโน1-n-[5-(4-เมธิล-1h-อิมิดาโซล-1-อิล)-3-(ไตรฟลูออโรเมธิล)ฟีนิล] เบนซาไมด์ชนิดปลดปล่อยทันที
IN2013CH00918A (es)